TEMPO.CO, Jakarta – Two members of State Owned Enterprises or BUMN Pharmaceutical Holding, namely PT Kimia Farma Tbk and PT Indofarma Tbk, currently able to produce drugs for treatment Covid-19.
Kimia Farma has been able to produce Favipiravir which can be used for Covid-19 therapy, while Indofarma is ready to market anti-Covid-19 Remdesivir under the trade name Desrem. This drug is manufactured by Mylan Laboratories Limited, under license from Gilead Sciences Inc, Foster City and the United States of America.
President Director Holding BUMN Pharmacy, Honesti Basyir, say bIt is hoped that the joining of the pharmaceutical BUMN entity in the auspices of a holding company is expected to assist the government in accelerating the response to the Covid-19 pandemic in Indonesia, both in terms of prevention through the provision of vaccines, treatment through medication and provision of multivitamins, and through the provision of medical devices. This was conveyed on the sidelines of the coordination meeting of the BUMN Pharmacy Holding in Jakarta, Sunday, 4 October 2020.
Apart from Favipivar, Kimia Farma and its subsidiary, PT Phapros Tbk, too have been successfully also produces several drugs for handling Covid-19, antara lain Chloroquine, Hydroxychloroquine, Azithromycin, Favipiravir, Dexamethasone dan Methylprednisolon.
“Kimia Farma also produces several endurance enhancing multivitamins, such as Vitamin C (tablets and injection), Becefort, Fituno and Geriavita as additional products to maintain endurance,”Usaid Verdi Budidarmo, President Director of Kimia Farma.
Verdi added, Favipiravir is the first product in Indonesia developed by BUMN, and have mGet a Circular Permit Number (NIE) from the Food and Drug Supervisory Agency (BPOM) and will be distributed to all health services in accordance with Government regulations.
In addition to medicines and multivitamins, Kimia Farma through its retail network also distributes medical devices such as masks, hand sanitizers and performs inspection services, namely the Rapid Test which is produced by Kimia Farma itself and PCR Test in all Kimia Farma health service networks spread throughout Indonesia. .
Meanwhile, Indofarma and all of its business groups support the Government’s efforts in suppressing the spread of Covid-19 in the country through various types of products., among others, Oseltamivir 75gr Caps which is a leading antiviral which has now become a reference as a treatment protocol Covid-19 in various rhome sakit.
Oseltamivir 75 gr Caps is a product that has a Domestic Content Level certificate worth 40.06 percent Indofarma has produced itself with a production capacity of 4.9 million kapsul for months, so that it is expected to be able to meet the needs of the Indonesian people.
Another product for handling Covid-19 is Desrem Remdesivir Inj 100 mg, which is an antiviral product produced by Mylan Laboratories Ltd, which will be marketed by Indofarma, in the near future.
“The product that we will market in the near future is Desrem Remdesivir Inj 100mg, which has received Emergency Use Authorization (EUA) approval in Indonesia and has been approved by BPOM through the issuance of a marketing permit number which was issued on September 30, 2020.,” said the President Director of Indofarma Arief Pramuhanto.
“Desrem Remdesivir 100mg inj will go on sale next week, a drug used for use in hospitalized patients with Covid-19 in moderate-severe conditions. Then for stock availability for this month, there are already as many around 400,000 vials at a price that is certainly affordable for the public,” he added.
Arief mengatakan, sApart from medicines, Indofarma has also produced medical devices such as 3Play Medical Face Mask (Inamask), Hand Sanitizer (Clind), Rapid Test (Smart Diagnostic Covid19) to Mobile Diagnostic Real Time PCR, Isolation Transport Products to Virus Transport Media (VTM). .
Meanwhile, Bio Farma as the holding company for the BUMN Pharmacy Holding, has the task of procuring the Covid-19 vaccine, which is the result of a collaboration with Sinovac, at which is currently still in the clinical trial stage in Bandung. Until the end of September 2020, 1.319 volunteers have received the first injection, 656 volunteers have received the second injection, and 244 volunteers are in the blood collection stage after the second injection. Until now, there have been no reports of serious post-immunization follow-up events (AEFI) due to vaccination that.
– .
